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Native nucleotides show a hyperbolic concentration
dependence of the pre-steady-state rate of incorpo-
ration while maintaining concentration-independent
amplitude due to fast, largely irreversible pyro-
phosphate release. The kinetics of 3’-azido-
2’,3’-dideoxythymidine (AZT) incorporation exhibit
an increase in amplitude and a decrease in rate
as a function of nucleotide concentration, implying
that pyrophosphate release must be slow so that
nucleotide binding and incorporation are thermo-
dynamically linked. Here we develop assays to
measure pyrophosphate release and show that
it is fast following incorporation of thymidine
5’-triphosphate (TTP). However, pyrophosphate
release is slow (0.0009s
 1) after incorporation of
AZT. Modeling of the complex kinetics resolves
nucleotide binding (230mM) and chemistry forward
and reverse reactions, 0.38 and 0.22s
 1, respec-
tively. This unique mechanism increases selectivity
against AZT incorporation by allowing reversal of
the reaction and release of substrate, thereby
reducing kcat/Km (7 10
 6kM
 1s
 1). Other azido-
nucleotides (AZG, AZC and AZA) and 8-oxo-7,
8-dihydroguanosine-5’-triphosphate (8-oxo-dGTP)
show this same phenomena.
INTRODUCTION
Nucleoside reverse transcriptase inhibitors (NRTIs) con-
tinue to be an integral part of the highly active
antiretroviral therapy (HAART) used to combat HIV
infections (1). The primary limiting factors of the current
treatments are the ability of HIV to rapidly develop
resistance to the drugs and the toxic side eﬀects of the
NRTIs. Each of the eight US Food and Drug
Administration (FDA) approved NRTIs are given orally
as inactive prodrugs that require subsequent phosphoryla-
tion by host cell kinases. In the triphosphate form they
act as substrates for HIV reverse transcriptase (RT)
and terminate DNA polymerization because they lack a
30-OH (2). Under most circumstances, the NRTIs cannot
be removed because RT lacks a proofreading exonuclease
activity, although mutations aﬀording resistance have
evolved by optimization of pyrophosphorolysis, the
reversal of the polymerization reaction but with ATP as
the pyrophosphate donor (3,4). Moreover, toxic side
eﬀects limit the dose and extent of therapy with many
NRTIs.
The toxicity of nucleoside analogs varies widely across
the series of eight NRTIs currently approved by the FDA.
For the most toxic analogs, side eﬀects are reminiscent of
heritable mitochondrial diseases and are the consequence
of duration-dependent mitochondrial dysfunction (5–11).
These analogs are thought to act as alternative substrates
for the mitochondrial DNA polymerase (Pol g), thus
slowing the replication of the mitochondrial genome.
In order to quantify the inhibition of mitochondrial genome
replication, we previously reconstituted and characterized
recombinant human Pol g holoenzyme in vitro (12,13). The
overall ﬁdelity of replication was established using transient
state kinetic methods (14–16). Measurements of the kinetics
of incorporation and exonuclease removal of each of the
FDA-approved NRTIs were used to compute a ‘toxicity
index’whichcorrelatedwellwiththeseverityoftheclinically
observed toxicities over six orders of magnitude (17,18).
This correlation held true for all of the analogs except
30-azido-20,30-dideoxythymidine (AZT or zidovudine). That
is, the low toxicity of AZT towards mitochondrial DNA
replication seen in vitro was at odds with the clinical
experience,therebysuggestingadiﬀerentsiteoftoxicaction.
Moreover, AZT primarily causes bone marrow toxicity,
while ddC (zalcitabine) and ddI (didanosine) produce
peripheralneuropathy,ahallmarkofmitochondrial toxicity
(19). There is a growing body of literature supporting the
notion that the toxicity of AZT may arise due to inhibition
at a site other than the mitochondrial DNA polymerase,
and so both clinical and enzymatic data suggest that
AZT does not signiﬁcantly inhibit human mitochondrial
DNA replication.
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of AZT by Pol g. The ‘toxicity index’ was based upon
the speciﬁcity constant (kcat/Km) for incorporation of
30-azido-2030-dideoxythymidine 50-triphosphate (AZT-TP)
relative to that of TTP and also the rate of exonuclease
removal of AZT. For all of the natural deoxynucleoside
triphosphates (dNTPs) and the NRTIs (in their tripho-
sphate form), the speciﬁcity constant was measured under
single turnover conditions ([E] > [DNA]) by measuring
the concentration dependence of the rate of incorporation
in a single nucleotide extension reaction. Following the
standard paradigm (20), the hyperbolic concentration
dependence of the observed rate of incorporation deﬁned
the maximum rate of polymerization (kpol) and the ground
state dissociation constant (Kd). Normally, the kpol/Kd can
be equated to kcat/Km, because the initial binding reaction
is a rapid equilibrium relative to the rate of incorporation
and is followed by a single, eﬀectively irreversible, rate-
limiting step. However, the kinetics of incorporation
using AZT-TP were complex and precluded an accurate
estimate for the speciﬁcity constant. The rate of incor-
poration appeared to decrease slightly with increasing
concentration, whereas the amplitude followed a hyper-
bolic dependence (17). This suggested that the formation of
enzyme-bound product (EDNAn+1 inorganic pyrophos-
phate, PPi) was reversibly linked to the nucleotide ground
state (EDNAndNTP). Qualitatively, this would explain
the fact that higher concentrations of AZT-TP appeared
to drive product formation at the active site of the enzyme,
but relied upon the unusual prediction that pyrophosphate
release was slow.
The most striking aspect of this hypothesis is that it
suggests a novel mechanism for the polymerase to correct
an aberrant incorporation event by holding on tightly to
the products, thereby favoring reversal of the reaction and
release of the substrate. In this report, our aim was to
further explore the mechanism governing the unusual
kinetics of incorporation of AZT and to better deﬁne the
speciﬁcity constant. Direct measurement shows that
pyrophosphate release after incorporation of AZT is
indeed slow, allowing binding and chemistry to be
reversibly linked. The kinetic behavior observed with
AZT-TP is also shown to be general for other azido-
analogs: 30-azido-20,30-dideoxyadenosine-50-triphosphate
(AZA-TP), 30-azido-20,30-dideoxycytidine-50-triphosphate
(AZC-TP) and 30-azido-20,30-dideoxyguanosine-50-tripho-
sphate (AZG-TP). This report also provides insights for
the recent observations concerning the incorporation
of (–)-b-L-20-30-dideoxy-5-ﬂuoro-30-thiacytidine ((–)FTC)
(21) and the potent mutagen 8-oxo-7,8-dihydroguanosine-
50-triphosphate (8-oxo-dGTP) (22).
MATERIALS AND METHODS
NRTItriphosphates andoligonucleotides
AZT-TP was obtained from Moravek Biochemicals
(Brea, CA, USA). AZA-TP, AZC-TP and AZG-TP were
purchased from TriLink Biotechnologies (San Diego, CA,
USA). All oligonucleotides were purchased from
Integrated DNA Technologies (Coralville, IA).
Enzymes
Recombinant human Pol g catalytic and accessory
subunits were obtained as previously described (12,13).
Holoenzyme was reconstituted at a 1:5 stoichiometric
ratio of catalytic subunit to accessory subunit in order to
saturate the binding with an apparent Kd of 35nM, and no
inhibition was seen due to excess accessory protein (13).
All of the experiments were conducted using an exonu-
clease-deﬁcient mutant (E200A). HIV-1 RT was obtained
similarly to previously published methods (23). Yeast
inorganic pyrophosphatase (PPase), purine nucleotide
phosphorylase and nucleoside diphosphate kinase (NDP
kinase) were purchased from Sigma-Aldrich Corp
(St Louis, MO).
Preparation of DNA
A DNA primer/template of 25 and 45nt, respectively,
was employed for all experiments except when terminated
with 30-azido-20,30-dideoxythymidine 50-monophosphate
(AZT-MP) or TMP for pyrophosphorolysis reactions, in
which case they were 26 and 45nt, respectively. The pri-
mer sequence was 50-GCCTCGCAGCCGTCCAACCA
ACTCA-30, and the template sequence was 50-GGA
CGGCATTGGATCGAGGXTGAGTTGGTTGGACG
GCTGCGAGGC-30, where the bold X in the template was
modiﬁed to provide the desired base pair for the particular
experiment being conducted. For most experiments the
primer was 50-
32P-labeled using T4 polynucleotide kinase
as previously described (22). Primers containing
30-terminal AZT-MP were created to examine the pyr-
ophosphorolysis reaction. A polymerase reaction was
performed using 1mM HIV-1 RT, 3mM duplex DNA
(containing the appropriate template base opposite the
26th primer position), and 50mM AZT-TP in the following
reaction buﬀer: 50mM Tris–Cl, pH 7.5, 100mM NaCl,
2.5mM MgCl2. The reaction was allowed to ensue for
30min at 378C and then the product was puriﬁed by
denaturing polyacrylamide gel electrophoresis (PAGE) to
obtain the AZT-MP terminated primer.
Incorporation andpyrophosphorolysis reactions
Unless otherwise stated incorporation assays were
performed at 378C in a buﬀer consisting of 50 mM
Tris–Cl, pH 7.5, 100 mM NaCl, 2.5mM MgCl2. The
methods for rapid mixing experiments were conducted
as previously reported (17).
Stopped-flow measurement of PPi release
A SF 2004 series stopped-ﬂow apparatus from
KinTekCorp.(Austin,TX,USA)wasusedforthemeasure-
ment. Exonuclease-deﬁcient holoenzyme (100nM) was
preincubated for 5min with 2.5 90mM Mg
2+,9 0 n M
25/45-mer DNA, 1.5mM Escherichia coli phosphate-
binding protein (PBP) mutant labeled at Cys197
with N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-
3-carboxamide (MDCC), 100mM 7-methylguanosine,
0.02 U/ml purine nucleotide phosphorylase and 0.005
U/ml yeast inorganic PPase. The solution was then
rapidly mixed at 20C with 2.5mM Mg
2+,5 0 mM TTP,
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tide phosphorylase. The ﬂuorophore was excited at 425
and a 450nm long pass ﬁlter was used to observe
emission. The coupled assay for phosphate release was
previously described but needed to be modiﬁed here by
the inclusion of yeast PPase (24). Control experiments
veriﬁed that the rate of hydrolysis of pyrophosphate to
phosphate was suﬃciently fast so that the kinetics was
solely limited by the release of PPi from Pol g.
Enzymatic synthesis of c-
32Plabeled AZT-TP
ATP g-
32P-labeled was obtained from Perkin Elmer
(Wellesley, MA, USA). AZT-DP was purchased from
Moravek Biochemicals (Brea, CA, USA). The phosphor-
ylation reaction was carried out in the same buﬀer as
described for incorporation assays at room temperature
for 1h with 600nM g-
32P-labeled ATP (3000Ci/mmol),
600nM AZT-DP and 0.1U/ml NDP kinase, at which time,
conventional rat kinesin was added to a ﬁnal concentra-
tion of 5 mM to rid the solution of unreacted g-
32P-labeled
ATP. The sample was loaded onto a 1ml DEAE
Sepharose FF (Amersham Biosciences, Piscataway, NJ,
USA) column at ﬂow rate of 1ml/min and a gradient of
0.1–1M triethylammonium (pH 7.5) was run to elute
g-
32P-labeled AZT-TP. The elution of product was
monitored by counting 10ml of each fraction using a
scintillation counter by standard methods. Peak fractions
were lyophilized to constant weight and resuspended in
10mM Tris–Cl, pH 7.5. Labeled and unlabeled AZT-TP
were combined at a ratio of 1:10000 for a stock
concentration of 3mM.
Measurement ofPPi releaseduring AZT-TP incorporation
Reactions were performed by manual mixing under single
turnover conditions (exact reaction conditions are listed in
the main text). The Pol g/DNA complex was mixed with
g-
32P-labeled AZT-TP and Mg
2+ to start the reaction.
At each time point a 40ml aliquot was taken and passed
through a BioSpin 30 (BioRad, Hercules, CA, USA) gel
ﬁltration column by centrifuging for 30s at 4000r.p.m.
The elution from each time point was spotted onto a PEI
cellulose F 20 20cm glass backed TLC plate (EM
Science) along with various amounts of g-
32P-labeled
AZT-TP to generate a standard curve. Imaging was
performed using a phosphorimager, Molecular Dynamics
Storm 860, and quantiﬁed using ImageQuaNT software
(Amersham Biosciences, Uppsala, Sweden).
Data fitting and analysis
The data for the time dependence of substrate depletion or
product formation for the various pre-steady-state experi-
ments reported were analyzed by non-linear regression
using the software GraFit 5 purchased from Erithacus
Software (Horley Surrey, UK). Data were ﬁtted using
exponential functions with the general form of the
following equation:
Y ¼
X
i
Aie kit þ C 1
where Y is a value corresponding to the concentration or
signal observed for the species of interest, C is the oﬀset,
Ai is the observed amplitude (Aobs) and ki is the observed
rate constant (kobs). In the main text the speciﬁc equations
used are referred to as single, double or triple exponential
equations and correspond to values of i=1, 2 or 3,
respectively.
Data from the single nucleotide incorporation reactions
were ﬁtted using single or double exponential equations to
extract the observed reaction amplitude(s) and rate(s) and
when appropriate the data were ﬁtted using the following
hyperbolic functions describing the concentration
dependence:
Aobs ¼
Amax½S 
Kd þ½ S 
2
In the above equation, Amax is deﬁned as the maximum
amplitude at inﬁnite substrate (S) concentration and Kd is
the ‘apparent’ dissociation constant.
It was seen that for incorporation reactions using AZT-
TP, the observed rate of reaction decreased hyperbolically
as a function of increasing substrate concentration and
was therefore ﬁtted using the equation shown below. Also,
a direct competition experiment was performed where the
rate of incorporation was measured using TTP in the
presence of increasing concentrations of AZT-TP and was
analyzed similarly.
kobs ¼ kobs
½S 
Kd,app þ½ S 
þ C 3
In the above equation ikobs is the predicted overall
change in the observed rate over the concentration series,
Kd,app is the ‘apparent’ dissociation constant and C is
the Y-intercept. The true Kd for AZT-TP binding was
obtained according to the following relationship:
Kd,app,AZTTP ¼ Kd,AZTTP 1 þ
½dTTP 
Kd,dTTP
  
4
The kinetic parameters for TTP incorporation were
previously measured under identical conditions (15).
The concentration dependence of the rate of pyrophos-
phorolysis of TMP from the 30-terminus of a primer
followed a hyperbolic relationship and was analyzed by
ﬁtting the data using the following equation:
kobs ¼
kmax½S 
Kd þ½ S 
5
where, kmax is the predicted rate of pyrophosphorolysis at
inﬁnite PPi concentration.
Global datafitting
Pre-steady state and steady-state data were ﬁtted simulta-
neously using the program KinTek Global Kinetic
Explorer (KinTek Corp, Austin, TX, USA). The best ﬁt
was obtained using the Levenberg–Marquat method of
least-squares ﬁtting based upon numerical integration of
the rate equations. Data were normalized to reduce
Nucleic Acids Research, 2007, Vol. 35, No. 20 6975unequal weighting of errors between the two experiments.
Error estimates were based upon the covariance matrix.
RESULTS
Kinetics of incorporation
We previously reported that the single nucleotide incor-
poration of AZT-TP catalyzed by Pol g under single
turnover conditions was complex compared to that of the
other NRTIs examined (17). The kinetics indicated that
the amount of product formed in a single turnover was a
function of the concentration of AZT-TP in solution. This
implied that product formation was reversibly linked to
substrate binding. Given the importance of AZT in
treating HIV infections and the current debate over the
site of the observed clinical toxicities, we thought that it
was important ﬁrst to exclude the possibility that the
abnormal kinetics were a result of an artifact due to the
incomplete or insuﬃcient quenching of enzyme activity
upon the addition of 0.5M EDTA, as was routinely
employed. Therefore, we carried out a similar series of
reactions, but instead quenched with a ﬁnal concentration
of 0.5M HCl. The results are shown in Figure 1A. The
data appear to be similar to our previous data, in that, the
amplitude of product formation increased in a hyperbolic
fashion as a function of AZT-TP concentration
(Figure 1B). A ﬁt of the data using a hyperbolic function
[Equation (2)] deﬁned an apparent Kd for AZT-TP
binding of 160   40mM and a maximum amplitude of
59   7nM. In addition, we observed a decrease in the
observed rate of incorporation over the concentration
series, although the rate measurements at the two lower
concentrations were less accurate because of the lower
amplitudes. The observed rates of incorporation appeared
to decrease hyperbolically over the concentration series
and were therefore ﬁtted using Equation (3) to obtain an
apparent Kd of 25   10mM and an overall decrease in the
observed rate from  1.1 to 0.2s
 1 (net change of 0.95  
0.23s
 1). This experiment shows that there is no obvious
artifact due to using EDTA to quench the reaction and
conﬁrms our previous observation that the kinetics are
complex and not explained by the conventional model.
Although the standard pathway of the minimal steps
involving nucleotide binding, chemistry and product
release is presumably maintained as shown in Scheme 1,
the rate constants observed with AZT must be very
diﬀerent. The data suggest that the binding of AZT-TP is
reversibly linked to product formation, a conclusion that
requires either pyrophosphate is able to rebind to the
enzyme and react at a rate comparable to the forward
reaction (0.2s
 1), or, alternatively, that rate of pyrophos-
phate release must be very slow. To explore these
possibilities, we ﬁrst examined the kinetics of the reverse
reaction.
Kinetics ofpyrophosphorolysis
To measure the rate constant for the reverse reaction
(pyrophosphorolysis), a primer strand was synthesized
with AZT-MP located at the 30-terminus (26-mer) then
puriﬁed, radiolabeled and annealed to a complementary
template strand (45-mer). Pol g (100nM) was incubated
with the DNA duplex (90nM) and then mixed with
various concentrations of inorganic pyrophosphate (PPi)
and Mg
2+ to initiate the reaction. To our surprise, no
pyrophosphorolysis reaction was observed. The experi-
ment was repeated using various conditions at concentra-
tions of PPi up to 10mM with no observable depletion
of 26-mer. To determine whether this was an intrinsic
property of Pol g, the same experiment was repeated with
A
B
µ
Figure 1. Kinetics of AZT-TP incorporation by Pol g.( A) Exonuclease-
deﬁcient holoenzyme (100nM) was preincubated with 90nM 25/45-mer
DNA (radiolabeled primer) and then rapidly mixed with Mg
2+ and
various concentrations of AZT-TP [25 (open circle), 75 (ﬁlled circle),
150 (open square), 250 (ﬁlled square), 375 (open triangle) and 500mM
(ﬁlled triangle)]. Each data set was ﬁtted using a single exponential
equation to obtain the observed rate and reaction amplitude. (B) The
reaction amplitudes were plotted as a function of AZT-TP concentra-
tion (ﬁlled circle). The data were ﬁtted by non-linear regression using
Equation (2) to yield an apparent Kd of 160 40mM and maximum
amplitude of 59 7nM. The observed rates were also plotted as a
function of AZT-TP concentration (open square) and analyzed
according to Equation (3) to yield an apparent Kd of 25 10mM, an
overall predicted decrease in the observed rate of 0.95 0.23s
 1, and
a Y-intercept of 1.1 0.2s
 1.
E·Dn+ AZTTP E·Dn·AZTTP E·Dn−AZT ·PP
Kd k2
k−2
k3
E·Dn-AZT + PPi
Scheme 1. Minimal model for AZT incorporation.
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diﬀerent with nearly complete depletion of the 26-mer to
lengths as short as 6-mer (data not shown). Unfortunately,
this experimental format did not allow the accurate
quantiﬁcation of the reaction kinetics because lengthening
of the primer strand was also fairly substantial, due to the
production of dNTPs over time.
It was clear that the radiolabel must be present in the
terminal base rather than the 50-terminus to make an
accurate rate measurement. Therefore, a double mixing
experiment was performed where, in the ﬁrst mixing event,
Pol g/DNA complex (coding for T incorporation) was
mixed with a-
32P-TTP and allowed to react for 5s to obtain
full incorporation. In the second mixing event this solution
was combined with varying concentrations of PPi and
2.5mM Mg
2+, plus 20mM TTP. The cold TTP was neces-
sary to trap radiolabeled TTP in solution. The results are
shown in Figure 2. The time dependence of the disap-
pearance of 26-mer was monophasic and therefore ﬁtted
using a single exponential equation to extract the observed
rate for each concentration of PPi used. The observed rates
of reaction followed a hyperbolic concentration depen-
dence to yield a maximum rate of pyrophosphorolysis of
1.4   0.3s
 1 and a Kd of 240   80mM. Pol g was able to
catalyze the reverse reaction eﬃciently, but only using a
naturally terminated primer strand. These results were
counter to our hypothesis that a substantial reverse rate
constant for phosphoryl transfer was the cause of the
abnormal kinetics of incorporation using AZT-TP.
Roleof free PPi
Some other approaches were taken in an attempt to probe
any possible eﬀect of free PPi on the kinetics of the
incorporation reaction. First, the incorporation reaction
was performed in the presence of yeast inorganic PPase
included in the reaction mixture in order to hydrolyze PPi
to Pi rapidly. The kinetics of the incorporation reaction
using 200mM AZT-TP were nearly identical regardless of
whether or not PPase was included (data not shown). This
suggests that any role PPi may have on the abnormal
kinetics of the incorporation must occur prior to
dissociation from the enzyme. To further test this result,
the same incorporation reaction was performed except
that PPase was omitted and varying concentrations of PPi
were included. There was no obvious diﬀerence in the
reaction kinetics obtained at concentrations of PPi up to
1mM. At concentrations greater than 1mMP P i, the DNA
substrate degraded at a rate comparable to that of the
incorporation reaction and rendered the data diﬃcult to
interpret rigorously. In any event, we would expect a
maximum concentration of only 60nM PPi to build up in
solution during the incorporation reaction. Therefore,
these experiments clearly showed that free PPi has no
eﬀect on the apparently reversible nature of the incorpora-
tion reaction.
Hydrolysis of AZT-TP
Unable to observe a role for free PPi on the reaction kinetics
itseemedpossiblethatperhapstheconcentration-dependent
amplitude when using AZT-TP could be explained by
hydrolysis rather than pyrophosphorolysis. However, the
experiments were performed with exonuclease-deﬁcient
Pol g so hydrolysis by the usual mechanism would not be
likely, but may be occurring at the polymerase-active site.
If this was taking place, one might expect to see an
accumulation of AZT-MP in solution. In order to
investigate this, a single-turnover experiment ([E]>[DNA])
was performed using a relatively low concentration of AZT-
TP (75mM). As judged by anion-exchange chromatography
of the reaction mixture, no conversion of AZT-TP to either
AZT-DP or AZT-MP was observed up to 110min of
incubation time (data not shown).
Direct measurement of PPi release following
incorporation using TTP
The next obvious question was regarding the kinetics of
PPi release following the chemical reaction. It appeared
PPi
A
B
M µ
Figure 2. Pyrophosphorolysis of TMP-terminated primer. (A)
Exonuclease-deﬁcient holoenzyme (100nM) was preincubated with
90nM 25/45-mer DNA (radiolabeled primer) and mixed with 400nM
a-
32P-TTP in the presence of 2.5mM Mg
2+. The reaction was aged for
5s to permit radiolabeled TTP incorporation. A second mixing event
then combined this with varying concentrations of PPi [15 (ﬁlled circle),
30 (open circle), 75 (ﬁlled square), 200 (open square), 400
(ﬁlled triangle) and 1000 (open triangle) mM] in solution with 2.5mM
Mg
2+ and 20mM unlabeled TTP. The unlabeled TTP was included to
prevent the undesired incorporation of radiolabeled TTP following the
pyrophosphorolysis reaction. Shown is the concentration of the 26-mer
plotted as a function of time and the data were analyzed by non-linear
regression using a single exponential equation to obtain the observed
rate constants at the various PPi concentrations. (B) The observed
reaction rates were plotted versus the concentration of PPi used and
ﬁtted using Equation (5) to yield a maximum rate of pyrophos-
phorolysis of 1.4 0.3s
 1 and a Kd of 240 80mM.
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inﬂuence on the reaction amplitude. The data seemed to
be suggesting that the dissociation of PPi was not
occurring rapidly following the formation of product.
Therefore, it was of interest to measure the rate of PPi
release during the forward reaction. An assay was
developed using TTP in order to be sure that it was
capable of quantifying PPi dissociation accurately. The
fundamental component in obtaining a signal was
the mutant MDCC-labeled phosphate-binding protein
(MDCC-PBP) that was developed for monitoring the
release of Pi (24). This protein exhibits a rapid and large
ﬂuorescence increase upon binding Pi. However, PPi does
not bind and induce a ﬂuorescence change, so in order for
this assay to function, yeast inorganic PPase was included.
Shown in Figure 3A (smooth line) is the ﬂuorescent signal
collected when an incorporation reaction was performed
under single turnover conditions with a saturating
concentration of TTP. To compare this to the kinetics of
the incorporation reaction, an experiment was performed
in the chemical quench ﬂow with a radiolabeled primer
strand. The results are plotted along with the stopped-ﬂow
data in Figure 3A. The quench-ﬂow data overlay the
ﬂuorescence trace even though one is measuring PPi
release and the other is measuring the formation of
DNAn+1. In addition, there is no observable lag phase in
the stopped-ﬂow ﬂuorescence data. These results indicate
that the rate constant for PPi dissociation must be at least
ﬁve times greater than the maximum rate of incorporation
using TTP ( 25s
 1 at 20C). It is quite possible that a
conformational change of the protein actually limits the
rate of PPi dissociation, but this data alone does not
provide such evidence, but sets a lower limit on the rate
of PPi release of approximately ﬁve times the observed
rate, 125s
 1.
The overall goal of developing this assay was to
measure the rate of PPi dissociation using AZT-TP as
the substrate. Therefore, the same experiment was
performed with AZT-TP but it failed to produce any
clear signal. This provided the ﬁrst direct evidence that PPi
dissociation was not rapid following incorporation. It is
important to note that PPi release occurring at a rate
comparable to that of the rate of incorporation using
AZT-TP ( 0.2s
 1) would have been easily measured
under these conditions, but a much slower reaction could
not have been measured because of the presence of the
phosphate mop included to scavenge traces of phosphate
and improve sensitivity (24).
PPi releaseusing AZT-TPas asubstrate
To examine the apparently much slower rate of release of
PPi following AZT-TP incorporation, a diﬀerent experi-
mental approach was needed. The experiment required
the synthesis of g-
32P-labeled AZT-TP to perform this
measurement. We then used rapid size exclusion chroma-
tography to monitor the release of
32P-PPi from the
enzyme–DNA complex after incorporation. Pol g (1mM)
was then incubated with DNA (900nM) and mixed with
g-
32P-AZT-TP (300mM) to start the reaction. Then as a
function of time, samples of the reaction mixture were
applied to a small centrifugal size exclusion column in
order to remove any free or loosely associated radiola-
beled small molecules. As a result, the quantity of
radioactivity in the eluant was due to only tightly
associated enzyme-bound PPi (E
gDNAn
gAZT-TP plus
E
gDNAn+1
gPPi). The concentration of bound label was
quantiﬁed according to a standard curve to give the results
shown in Figure 3B.
There was a transient rise and fall in the concentration
of enzyme-bound radioactivity. The rate and amplitude of
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Figure 3. Comparison of PPi release following incorporation using TTP
or AZT-TP. (A) Exonuclease-deﬁcient holoenzyme (100nM) was
preincubated for 5min with 2.5mM Mg
2+, 90nM 25/45-mer DNA,
1.5mM E. coli PBP mutant labeled at Cys197 with the ﬂuorescent
compound MDCC, 100mM 7-methylguanosine, 0.02 U/ml purine
nucleotide phosphorylase and 0.005 U/ml yeast inorganic PPase and
then rapidly mixed in the stopped-ﬂow apparatus at 208C with 2.5mM
Mg
2+,5 0 mM TTP, 100mM 7-methylguanosine, and 0.02U/ml purine
nucleotide phosphorylase. PPi dissociation was monitored by observing
the change in ﬂuorescence that results from Pi binding to the MDCC-
labeled PBP (smooth line). Shown also are quench-ﬂow data from
a parallel experiment monitoring the DNAn+1 formation using a
radiolabeled primer strand (ﬁlled circle). (B) Exonuclease-deﬁcient
holoenzyme (1mM) was preincubated with 900nM 25/45-mer DNA and
mixed with 300mM g-
32P-labeled AZT-TP and 2.5mM Mg
2+ to start
the reaction. The amount of PPi (or PPi in equilibrium with AZT-TP)
that remained associated with Pol g as a function of time is shown on
the plot. The data were ﬁtted to a double exponential equation to
obtain an observed fast phase rate and amplitude of 1.2 0.3min
 1
and 700 70nM, respectively. The observed rate and amplitude of the
slow phase were 0.007 0.002min
 1 and 700 50nM, respectively.
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 1 and 700   70nM,
respectively, and the rate and amplitude of the slow phase
were 0.007   0.002min
 1 and 700   50nM, respectively.
This experiment clearly demonstrates that PPi remains
tightly associated with the enzyme on a time scale far
greater than that of the incorporation reaction. The
absolute amplitude of the radioactivity also shows that
less than one radiolabeled molecule associated with Pol g.
From this and previous experiments, it can be concluded
that PPi is not released rapidly from the active site
following the incorporation reaction in contrast to the
reaction using TTP. The outcome of very slow PPi release
is that it must allow the chemical reaction to occur in the
reverse direction and therefore provides an avenue for
enzyme-bound product to come to equilibrium with free
substrate.
The observed rate of the rise ( 0.02s
 1) was slower
than the observed rate of incorporation (0.2s
 1), but the
time resolution of the method was insuﬃcient to resolve
the rate of incorporation directly. The rate of the slow
decline provides a semi-quantitative estimate of the rate of
PPi release of  0.0001s
 1.
Estimates ofKdforAZT-TP incompetition withTTP
Because the concentration dependence of the kinetics of
incorporation of AZT are complex (Figure 1), estimates
for the Kd for ground state nucleotide binding of AZT-TP
were dependent upon the model used to ﬁt the data.
Therefore, we measured the Kd for AZT-TP by competi-
tion against TTP in a single nucleotide incorporation. This
assay was possible because of the dramatic diﬀerence in
the rate of incorporation of TTP (kpol   25s
 1) compared
to that for AZT-TP so that AZT-TP binds but is not
incorporated on the time scale of a single turnover
of incorporation of TTP. The observed rate of TTP
incorporation at a concentration of 1mM (close to the Kd
for TTP) was measured in the presence of various
concentrations of AZT-TP under single turnover condi-
tions (Figure 4). The observed rate of incorporation
decreased hyperbolically as a function of increasing AZT-
TP concentration with an apparent Kd of 53   13mM
[Equation (3)]. The Kd for TTP (0.63mM) was previously
measured under these conditions and was used according
to the relationship shown in Equation (4) to determine a
true Kd of 20   7mM for AZT-TP. This estimate of the Kd
obtained by this method is 8-fold tighter than that
predicted previously by analyzing the obvious amplitude
change of the single nucleotide incorporation reactions
(Figure 1B). However, this estimate appears to mirror the
apparent Kd obtained from the hyperbolic ﬁt of the
decrease in the observed rate (Figure 1B).
Steady-state kinetics of AZT-TPincorporation
Under normal circumstances, the speciﬁcity constant (kcat/
Km) for the incorporation of nucleotides is more
accurately obtained using transient state kinetic methods,
and because DNA release is slower than incorporation
conventional, steady-state methods fail to provide kinetic
parameters that accurately reﬂect nucleotide selectivity
during processive synthesis. In the present case, however,
our data suggest that pyrophosphate release is much
slower than DNA release, and therefore, steady-state
methods should provide a valid estimate of kcat/Km. In this
unusual case, the relevant kinetic parameters could be
determined by measuring the steady-state kinetics of single
nucleotide incorporation. The time dependence of product
(DNAn+1) formation is shown under steady-state condi-
tions with DNA in excess of Pol g (Figure 5). The data
were analyzed by linear regression, and the observed rate
was plotted as a function of concentration deﬁning a kcat
of 0.001   0.0001s
 1 and a Km of 280   60mM. It is
important to note that the kcat obtained for this
incorporation reaction is 20-fold slower than the rate of
DNA release (13). The overall rate of catalysis in this case
may be partially limited by a conformational change
which limits the release of both PPi and DNAn+1. The
speciﬁcity constant deﬁned by this experiment is almost
M
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Figure 4. Determination of the Kd for AZT-TP in competition with
TTP. (A) Exonuclease-deﬁcient holoenzyme (100nM) was preincubated
with 90nM 25/45-mer DNA (radiolabeled primer) and then rapidly
mixed with Mg
2+,1 mM TTP and various concentrations of AZT-TP
[0 (open circle), 50 (ﬁlled circle), 200 (open square) and 400 (ﬁlled
square) mM]. Each data set was ﬁtted using a single exponential
equation to obtain the observed rate of incorporation. (B) The
observed rates were plotted as a function of AZT-TP concentration
and ﬁtted using Equation (3) to obtain an apparent Kd of 53 13mM
for AZT-TP binding, a Y-intercept of 9.7 0.3s
 1, and an overall
decrease in the observed rate of 8.6 0.6s
 1. According to
Equation (4), a true Kd of 20 7mM for AZT-TP in competition
with TTP can be deﬁned.
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 6mM
 1s
 1) than previously
reported (17) or computed from the rate of the single
turnover divided by the apparent Kd deﬁned by the
amplitude dependence (Figure 1).
Previous measurement of AZT incorporation by steady-
state methods provided an estimate of 1   10
 4mM
 1s
 1
and a discrimination of 12700 against AZT-TP relative to
TTP (25). Although kcat/Km values reported by Lim et al.
are reasonably close to our measurements, they grossly
underestimated discrimination by reference to the artiﬁ-
cially slow rate of TTP incorporation, limited by DNA
release in the steady-state measurements. DNA release
does not limit the steady-state rate of AZT-TP incorpora-
tion, but it does limit the rate of TTP incorporation.
Kineticsofincorporationoftheother3’-N3-substitutedNRTIs
The only structural diﬀerence between TTP and AZT-TP
is that the normal 30-hydroxyl has been substituted with an
azide group. Therefore, the complex kinetics of incorpora-
tion is a direct consequence of the azide substitution.
In order to determine whether the eﬀect of the azide is
general, the other three nucleoside analogs were examined.
The single nucleotide incorporation reactions for AZA-TP
(dATP analog), AZC-TP (dCTP analog) and AZG-TP
(dGTP analog) were carried out in the same fashion as
that detailed for AZT-TP and the data obtained are shown
in Figure 6. The kinetics of incorporation strongly
resembled that of AZT-TP, even though the data collected
with AZA-TP and AZC-TP were biphasic. The amplitude
of the fast phase of the reaction for both analogs was
clearly dependent on the concentration of substrate in
solution, while the rate of the fast phase was not
(Figure 6A–D). The incorporation assay using AZG-TP,
on the other hand, was much slower and monophasic,
although the reaction amplitude still appeared to vary
with concentration (Figure 6E and F). One signiﬁcant
diﬀerence between AZG-TP and the other three analogs
was that the rate clearly increased linearly over the
concentration range examined.
DISCUSSION
Several signiﬁcant observations were taken during the
course of this work, but none were more signiﬁcant than
the discovery that the release of PPi is extremely slow
following incorporation using AZT-TP. The ramiﬁcations
of this can be seen in both the single turnover incorpora-
tion reactions and in the steady-state kinetic parameters.
In the single turnover reactions, the data clearly demon-
strate that the equilibrium amount of DNAn+1 achieved
during the steady state at the active site is a function of the
free AZT-TP concentration. This is in contrast to the
correct incorporation reaction using TTP where, appar-
ently, any conformational changes and PPi dissociation
are extremely rapid. Clearly, we were not able to directly
measure the conformational changes of Pol g, but the fact
that we were not able to force the pyrophosphorolysis
reaction to take place by adding a relatively high
concentration of PPi to the Pol g/DNA complex (primer
terminated with AZT-MP) suggests that when AZT-MP is
bound, Pol g is unable to productively associate with PPi
from solution. In contrast, the reverse reaction using a
naturally terminated DNA substrate was readily catalyzed
upon addition of PPi to solution.
Here we show that the rate of PPi release after
incorporation of TTP must be quite fast because the two
reactions are coincident (Figure 3A). Similarly, we
presume that translocation is also fast and must follow
rapidly after the release of PPi, but this conclusion is based
solely on our inability to show a delay in the ability of the
enzyme to bind the next nucleotide after a single
incorporation event (20,26,27). Our assays reported here
provide the ﬁrst direct evidence that PPi release is fast after
incorporation of a normal nucleotide. They do not bear
on the question of translocation. However, because
translocation is operationally deﬁned by the ability to
bind the next nucleotide, it must follow PPi release.
In addition, we presume that Pol g, like better character-
ized Pol A family polymerases (28), undergoes a change in
M
A
B
µ
Figure 5. Steady-state kinetic parameters of AZT-TP incorporation.
(A) Exonuclease-deﬁcient holoenzyme (100nM) was preincubated with
1.5mM 25/45-mer DNA (radiolabeled primer) and mixed with Mg
2+
and various concentrations of AZT-TP [50 (ﬁlled triangle), 100 (open
triangle), 200 (ﬁlled square), 300 (open square), 400 (ﬁlled circle) and
500 (open circle) mM]. The data were ﬁtted by linear regression and the
slope divided by the enzyme concentration to obtain the rate of
turnover. (B) The rate of turnover was plotted against AZT-TP
concentration and the data were analyzed according to the Michaelis–
Menton equation to obtain a kcat of 0.001 0.0001s
 1 and a Km of
280 60mM.
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therefore likely, that a conformational change to return to
the ‘open’ state after incorporation limits the rates of PPi
release and translocation.
The most remarkable observation reported here is the
exceedingly slow release of PPi after incorporation of
AZT. Because this rate is even slower than the rate of
DNA release (0.02s
 1), it is reasonable to suppose that the
[AZA-TP] (µM)
[AZC-TP] (µM)
[AZG-TP] (µM)
A B
D C
E F
Figure 6. Kinetics of incorporation using azide-substituted analogs. (A) Exonuclease-deﬁcient holoenzyme (100nM) was preincubated with 90 nM
25/45-mer DNA (radiolabeled primer) and then rapidly mixed with Mg
2+ and various concentrations of AZA-TP [50 (open triangle), 100 (ﬁlled
square), 200 (open square), 300 (ﬁlled circle) and 400mM (open triangle)]. Each data set was ﬁtted using a double exponential equation. (B) The
amplitude for fast phase of each reaction was plotted as a function of AZA-TP concentration (ﬁlled circle). A ﬁt of the data to Equation (2). yields
an apparent Kd of 800 120mM and a maximum amplitude of 65 8nM. The observed rate of the fast phase of each reaction was also plotted as a
function AZA-TP concentration (open square). (C) Single turnover reaction performed using AZC-TP [10 (open triangle), 35 (ﬁlled square), 65 (open
square), 150 (ﬁlled circle) and 300mM (open circle)]. (D) The amplitude was plotted as a function of AZC-TP concentration (ﬁlled circle). A ﬁt of the
data predicts an apparent Kd of 96 6mM and a maximum amplitude of 64 2nM. The observed rate of the fast phase of each reaction was also
plotted (open square). (E) Single turnover reaction using AZG-TP [50 (ﬁlled triangle), 100 (open triangle), 200 (ﬁlled square), 325 (open square), 450
(ﬁlled circle) and 600 mM (open square)]. Each data set was ﬁtted using a single exponential equation. (F) The amplitude was plotted as a function of
AZG-TP concentration (ﬁlled circle) to deﬁne an apparent Kd of 50 10mM and a maximum amplitude of 81 3 nM. The observed rate of each
reaction was also plotted and ﬁtted by linear regression to obtain a slope of (7.5 0.5)   10
 5mM
 1min
 1and a Y-intercept of 0.028 0.002min
 1
(open square).
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reaction tightly bound. Maintenance of the closed state
would then limit the release of PPi and DNA. Homology
modeling has suggested that an active site lysine residue
may sterically clash with the azido group to limit binding
(29). However, we must await solution of the crystal
structure of Pol g with AZT bound to assess whether this
suggestion is true, and how we might then understand the
slower PPi release rates.
The eﬀect of slow PPi release on the eﬃciency of AZT-
TP incorporation by Pol g is quite large. The commitment
to forward catalysis is not made until PPi dissociates from
the enzyme, predicting that the speciﬁcity constant for
incorporation should be correspondingly low. An unam-
biguous measurement of kcat/Km found this to be the case
and dictates that our previous calculation of the dis-
crimination ((kcat/Km)TTP/(kcat/Km)AZT-TP) against AZT-
TP be revised to (1   0.5)   10
7, almost 300-fold greater
than previously estimated. Interestingly, the discrimina-
tion against AZT-TP is over an order of magnitude
greater than that of (–)-cis-2-amino-1,9-dihydro-
9-(4-hydroxymethyl)-2-cyclopenten-1-yl)-6H-purine-6-one
triphosphate (CBV-TP) which was previously suggested to
be the least toxic FDA approved NRTI towards
mitochondrial genome replication (17,18). Therefore, we
must conclude that AZT in the triphosphate form is
predicted to have little to no eﬀect on the overall rate of
mitochondrial genome replication. In agreement with
these studies, recent observations suggest that AZT may
be a potent inhibitor of thymidine kinase and that
depletion of mitochondrial DNA is actually due to much
lower than normal levels of TTP (30). Of course, extremely
low levels of TTP may tend to provide an unusually high
probability of incorporation compared to the other
NRTIs simply due to the lack of a direct competition
between TTP and AZT-TP.
To get the best estimates for the kinetic parameters
governing incorporation of AZT-TP, we globally ﬁt the
data from the pre-steady state and steady-state experi-
ments (Figures 1A and 5A, respectively) by non-linear
regression based upon numerical integration of the rate
equations. The results of this global analysis in ﬁtting the
data to Scheme 1 are shown in Table 1. This simple model
and set of rate constants adequately accounts for most,
but not all of the data. Namely, it fails to account for the
12-fold tighter binding in competition with TTP
(Kd=20mM, Figure 2) and the apparent decrease in the
rate of incorporation as a function of increasing nucleo-
tide concentration (Figure 1B). These data could be
accounted for if we proposed a more complex model,
such as by including isomerization of the enzyme-bound
DNA between productive and non-productive states, or
by proposing the binding of a second AZT-TP molecule.
The simple model adequately accounts for the observed
dependence of the amplitude of the burst on AZT-TP
concentration but not the apparent decrease in rate
(Figure 1B). However, there are large errors in the data
suggesting a decrease in rate as a function of AZT-TP
concentration, thereby weakening arguments in support of
a more complex model. In the absence of additional data
to test either of our more complex models, we settled on
the minimal model (Scheme 1) as suﬃcient to account for
the data without introducing additional undeﬁned steps in
order to achieve an incremental improvement in the
quality of the ﬁt. Further experimentation is required to
look for additional AZT-binding sites or multiple states of
bound DNA.
The fact that there is an equilibrium formed between
free AZT-TP and the product, DNAn+1, aﬀords the
polymerase with a novel type of proofreading mechanism
that, simply stated, is catalysis of the reverse reaction
resulting from the slow rate of pyrophosphate release. It is
reasonable to suppose that a conformational change
following chemistry in the forward direction may limit
PPi dissociation, thus allowing time for the reverse
reaction to occur.
Previous data on the incorporation of 8-oxo-dGTP, a
naturally occurring, oxidatively damaged and highly
mutagenic nucleotide, displayed similar kinetic behavior
(22). We proposed that Pol g may have evolved a novel
pathway to reduce incorporation of 8-oxo-dG to supple-
ment to the eﬀect of exonuclease proofreading activity.
This mechanism would attenuate the toxic or mutagenic
properties of alternative substrates that may not be as
eﬃciently removed by the exonuclease domain compared
to a typical mismatch. For reasons we do not yet
understand, azido-nucleotides follow the same pathway
that may have originally evolved to minimize the
incorporation of 8-oxo-dG or other common damaged
and mutagenic nucleotides present in the mitochondria.
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